<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In the United States, approximately 16 million people have <z:mp ids='MP_0002055'>diabetes</z:mp>; 90-95% have type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>They are at increased risk of developing <z:hpo ids='HP_0000822'>hypertension</z:hpo> and <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>The benefits of treating <z:hpo ids='HP_0000822'>hypertension</z:hpo> in diabetic patients and the potential to delay complications and reduce mortality have been demonstrated in clinical trials </plain></SENT>
<SENT sid="3" pm="."><plain>Increasing evidence shows that angiotensin-converting enzyme (ACE) inhibitors and <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi> (<z:chebi fb="0" ids="48432">Ang II</z:chebi>) receptor blockers (ARBs) may be equally effective in delaying progressive <z:e sem="disease" ids="C0022658" disease_type="Disease or Syndrome" abbrv="">renal disease</z:e> in diabetic patients </plain></SENT>
<SENT sid="4" pm="."><plain>Large, multicentre trials are ongoing to confirm the efficacy and superior safety profile of ARBs in this population </plain></SENT>
</text></document>